Pediatric Urology Academy

Amin Afrasiabi, MD, Pediatric Urologist
  • 0.0 (0)
  • Medicine
  • Weekly

Pediatric Urology Academy is an evidence-based educational podcast hosted by Amin Afrasiabi, MD, Pediatric Urologist. Each episode explores pediatric urology through clinical cases, landmark studies, practical decision-making, surgical principles, and emerging research. Topics include posterior urethral valves, vesicoureteral reflux, hydronephrosis, UPJO, megaureter, neurogenic bladder, hypospadias, disorders of sexual development, pediatric stone disease, and reconstructive surgery. Designed for pediatric urologists, urologists, residents, fellows, and healthcare professionals worldwide.

  1. 6d ago

    Wilms Tumor in the Vena Cava: When Chemotherapy Is the Safer Operation

    A Wilms tumor extending into the inferior vena cava can look like a surgical emergency. Sometimes the safer oncologic decision is to wait. This episode examines venous tumor thrombus in Wilms tumor and asks when preoperative chemotherapy should be viewed not only as cancer treatment, but as surgical risk reduction. We explore renal-vein, infrahepatic, retrohepatic, suprahepatic, and atrial extension; the hepatic veins as a critical operative landmark; thrombus regression after chemotherapy; cardiopulmonary bypass; vascular control; pulmonary embolic risk; anticoagulation; and the staging consequences of thrombectomy. The central framework is: Height. Response. Control. How high does the thrombus extend? Does chemotherapy move it down the surgical complexity ladder? And what vascular strategy is required for safe removal? The key lesson is that technical resectability and oncologic wisdom are not the same thing. Sometimes the safest Wilms operation is the one chemotherapy allows you not to perform.

    Wilms Tumor in the Vena Cava: When Chemotherapy Is the Safer Operation

  2. Oct 26

    The Lung Nodules That Decide Radiation

    A few millimeters on chest CT can change the entire treatment pathway for a child with Wilms tumor. This episode examines the uncertainty behind pulmonary nodules: which lesions are truly metastatic, what chemotherapy response actually tells us, when persistent nodules still contain viable tumor, and when biopsy or metastasectomy can meaningfully change management. We explore the response-adapted logic of AREN0533, the limits of CT-only diagnosis, the role of 1p/16q loss and 1q gain, the evidence behind whole-lung irradiation, and why excellent overall survival can still conceal a high treatment burden. The central framework is: Identity. Kinetics. Biology. What is the nodule? How does it behave under treatment? And what does the tumor biology say about residual risk? In Wilms tumor, the most consequential lung nodule may be the one we classify incorrectly.

    The Lung Nodules That Decide Radiation

  3. Oct 25

    AREN2231: When Tumor Biology Starts Writing the Postoperative Prescription

    Wilms tumor treatment was once organized primarily around stage. AREN2231 is testing a more complex model. This episode examines how the Children’s Oncology Group is integrating anatomic stage with molecular biology and treatment response to determine who may need less therapy, who may need different therapy, and who may require intensification. We explore 1q gain, combined loss of heterozygosity at 1p and 16q, the specific role of 11p15, post-chemotherapy blastemal predominance, and the major de-escalation and escalation questions being tested in AREN2231. The episode also explains why prognostic biomarkers are not automatically predictive biomarkers, why trial questions should not be mistaken for established standards, and why precision Wilms therapy begins in the operating room with accurate staging, lymph-node sampling, and adequate tissue for central pathology and molecular testing. The central framework is simple: Anatomy tells us where the tumor is. Biology estimates its intrinsic risk. Response tells us what survived treatment.

    AREN2231: When Tumor Biology Starts Writing the Postoperative Prescription

  4. Oct 24

    One Tear Can Rewrite the Protocol

    A Wilms tumor can be completely removed and still become a stage III problem. This episode examines the events that can change local staging despite apparently successful surgery: tumor spill, preoperative rupture, biopsy, and positive margins. We explore why these events are not biologically equivalent, how COG and SIOP may interpret them differently, why imaging alone can misclassify rupture, and why an unnecessary biopsy can alter the entire treatment pathway. The deeper issue is not simply contamination. It is loss of certainty about local control. The episode also examines a critical methodological problem: a surgical event may not worsen overall survival if modern therapy compensates for it, yet it can still increase radiation exposure, chemotherapy intensity, and long-term treatment burden. In Wilms tumor, operative technique does more than remove the tumor. It helps determine the stage, the treatment, and the consequences the child carries afterward.

    One Tear Can Rewrite the Protocol

  5. Oct 23

    The Normal-Looking Node That Changes Treatment

    In Wilms tumor surgery, lymph-node sampling is not a technical afterthought. It is part of the staging operation. This episode examines why normal-looking nodes can still contain tumor, why suspicious nodes can be reactive, and why the purpose of sampling is not therapeutic lymphadenectomy but reduction of staging uncertainty. We also examine the evidence behind node counts, why detection studies should not be confused with survival studies, how confounding can make node yield look more powerful than it is, and why COG and SIOP nodal data cannot be transferred uncritically across different treatment sequences. The central lesson is simple: in Wilms tumor, a very small specimen can carry a very large treatment consequence.

    The Normal-Looking Node That Changes Treatment

  6. Oct 22

    COG vs SIOP: Why Two Successful Wilms Strategies Start in Opposite Directions

    Why does one major Wilms tumor system begin with nephrectomy while another begins with chemotherapy? This episode examines the deeper logic behind the COG and SIOP approaches. The real difference is not simply surgery first versus chemotherapy first. It is about which information each system chooses to preserve, and which uncertainty it accepts. We explore untreated staging, response biology, stage migration, biopsy, lymph-node sampling, venous thrombus, and why a technically successful nephrectomy may still be an oncologically poor operation. The central question is not which system is better. It is: what information do you need before treatment changes the tumor?

    COG vs SIOP: Why Two Successful Wilms Strategies Start in Opposite Directions

  7. Oct 20

    Season 6, Episode 20 — The Contradiction Map: Diagnose Biology Before Naming the Syndrome

    A 46,XY child can have a uterus. A 46,XX child can have virilized external genitalia. One patient can have two gonads that followed completely different developmental paths. These findings seem contradictory only if we expect every layer of sex development to agree. In this season finale of Pediatric Urology Academy, we build a reusable diagnostic framework for DSD: the Contradiction Map. Instead of starting with a syndrome name, we ask which developmental layer failed, when it failed, and which functions remain intact. We explore: • why karyotype, gonadal anatomy, Müllerian structures, external phenotype, mini-puberty, and puberty measure different biological events• how a uterus in a 46,XY child localizes the problem toward gonadal development or AMH signaling• why absent Müllerian structures with undervirilization shifts attention toward androgen production, metabolism, or action• how 46,XX virilization with a uterus points toward prenatal androgen exposure• why asymmetric gonads and ducts suggest spatial biology, mosaicism, or mixed differentiation• how mini-puberty and puberty add a time dimension to DSD diagnosis• why hormone ratios are clues rather than absolute diagnoses• how negative sequencing can still coexist with a clear biological diagnosis• why variants of uncertain significance should not override physiology• how to avoid appearance-first and gene-first diagnostic anchoring• how to integrate anatomy, endocrinology, developmental timing, and genomics into one mechanistic model The central framework: When two findings disagree, do not force them into a syndrome. Localize the biological failure between them. The contradiction is not the obstacle. The contradiction is the clue. Season 6 — Differences of Sex Development: Reconstruct the Biology Hosted by Amin Afrasiabi, MDPediatric Urology Academy

    Season 6, Episode 20 — The Contradiction Map: Diagnose Biology Before Naming the Syndrome

  8. Oct 19

    Season 6, Episode 19 — The Dysgenetic Gonad: Germ Cells, Fertility and Tumor Risk

    A dysgenetic gonad can contain hormonal function, potentially valuable germ cells, and oncologic risk at the same time. That is why the real question is not simply whether the gonad should stay or go. It is what biological value remains inside it—and what risk comes with preserving it. In this episode of Pediatric Urology Academy, we examine the dysgenetic gonad as three separate biological problems: endocrine function, germ-cell potential, and tumor risk. We explore: • why Y-chromosomal material alone does not determine malignancy risk• how abnormal germ cells, the dysgenetic gonadal environment, and genes such as TSPY interact• why tumor risk differs across complete gonadal dysgenesis, partial gonadal dysgenesis, mixed gonadal dysgenesis, androgen insensitivity, and other DSDs• how gonadal position, age, histology, and molecular diagnosis modify risk• the distinction between gonadoblastoma and germ-cell neoplasia in situ• why expert pathology is essential when evaluating dysgenetic gonads• why the presence of germ cells does not prove future fertility• how fertility preservation in prepubertal dysgenetic gonads remains investigational• why endocrine value must be considered before gonadectomy• the limitations of ultrasound, MRI, tumor markers, and biopsy for surveillance• why each gonad should sometimes be assessed independently• how delaying irreversible surgery can preserve autonomy when oncologic risk permits The central framework: Do not ask only whether a dysgenetic gonad is dangerous. Ask what function it still provides, what fertility potential it may contain, and what risk is created by leaving it in place. Season 6 — Differences of Sex Development: Reconstruct the Biology Hosted by Amin Afrasiabi, MDPediatric Urology Academy

    Season 6, Episode 19 — The Dysgenetic Gonad: Germ Cells, Fertility and Tumor Risk
See All (91)

About

Pediatric Urology Academy is an evidence-based educational podcast hosted by Amin Afrasiabi, MD, Pediatric Urologist. Each episode explores pediatric urology through clinical cases, landmark studies, practical decision-making, surgical principles, and emerging research. Topics include posterior urethral valves, vesicoureteral reflux, hydronephrosis, UPJO, megaureter, neurogenic bladder, hypospadias, disorders of sexual development, pediatric stone disease, and reconstructive surgery. Designed for pediatric urologists, urologists, residents, fellows, and healthcare professionals worldwide.

Information

  • Creator
    Amin Afrasiabi, MD, Pediatric Urologist
  • Years Active
    2026
  • Episodes
    91
  • Rating
    Clean
  • Copyright
    © Amin Afrasiabi, MD, Pediatric Urologist
  • Show Website
    Pediatric Urology Academy